- Lilly plans to buy Merida Biosciences for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases beyond its weight-loss and diabetes franchises.
- The drugmaker has announced more than $20 billion in deals in 2026 and is targeting earlier-stage medicines to diversify its pipeline.
Quotes
“Lilly to Buy Merida for $2.88 Billion in Autoimmune Push”